A Phase III randomized , placebo controlled, double-blind trial of Sorafenib plus Erlotinib Vs. Sorafenib plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma [BAY 43-9006/1297]
ID Number 09-1347
Principal Investigator(s)Josep Llovet
Department(s) or Division(s)
Liver Diseases
Description
The purpose of this study is to determine if patients who have liver cancer who receive the drug sorafenib with the drug erlotinib live longer than patients who receive sorafenib alone.
Contact Information
Hope Cassano
(212) 241-8903
hope.cassano@mssm.edu
Recruiting Patients: Yes